Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 15/20 | 0.67 |
| ▸ | GSK3A | P49840 | 8/20 | 0.67 |
| ▸ | MAPT | P10636 | 7/20 | 0.64 |
| ▸ | ATR | Q13535 | 1/20 | 0.52 |
| ▸ | AHR | P35869 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16704213 | 0.88 | GSK3B (0.65) | GSK3BGSK3AMAPTATR | |
| SCHEMBL16704088 | 0.87 | GSK3B (0.67) | GSK3BGSK3AMAPTATR | |
| SCHEMBL18126649 | 0.86 | GSK3B (0.58) | GSK3BGSK3AMAPTATR | |
| SCHEMBL16711031 | 0.85 | GSK3B (0.72) | GSK3BGSK3AMAPT | |
| SCHEMBL16702397 | 0.85 | GSK3B (0.68) | GSK3BGSK3AMAPTATR | |
| SCHEMBL16703867 | 0.85 | GSK3B (0.67) | GSK3BGSK3AMAPT | |
| SCHEMBL19417885 | 0.81 | GSK3B (0.63) | GSK3BGSK3AMAPTATR | |
| SCHEMBL16702598 | 0.81 | GSK3B (0.70) | GSK3BGSK3AMAPT | |
| SCHEMBL16702656 | 0.80 | GSK3B (0.68) | GSK3BGSK3AMAPTAHR | |
| SCHEMBL16703348 | 0.80 | GSK3B (1.00) | GSK3BGSK3AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3066092-B1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS GSK-3 INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2018-09-05 | — | — | EP | disclosed |
| US-9809573-B2 | Substituted pyridine derivatives useful as GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-07 | — | — | US | disclosed |
| US-9809573-B2 | Substituted pyridine derivatives useful as GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-07 | — | — | US | disclosed |
| US-9809573-B2 | Substituted pyridine derivatives useful as GSK-3 inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-11-07 | — | — | US | disclosed |
| US-20160289210-A1 | Substituted Pyridine Derivatives Useful as GSK-3 Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160289210-A1 | Substituted Pyridine Derivatives Useful as GSK-3 Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-10-06 | — | — | US | disclosed |
| US-20160289210-A1 | Substituted Pyridine Derivatives Useful as GSK-3 Inhibitors | BRISTOL MYERS SQUIBB CO (US) | 2016-10-06 | — | — | US | disclosed |
| EP-3066092-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS GSK-3 INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-09-14 | — | — | EP | disclosed |
| WO-2015069593-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015069593-A1 | SUBSTITUTED PYRIDINE DERIVATIVES USEFUL AS GSK-3 INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160289210-A1 | Substituted Pyridine Derivatives Useful as GSK-3 Inhibitors | GSK3B, GSK3A, GRIN3A | GSK3B 1/4885GSK3A 2/4885MAPT 402/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.